• Homepage
• About the Company
  Vision

  Working with Procognia

  Intellectual Property

  Management

  Board of Directors
• Solutions and Technology
  Glycoanalysis

  Biosimilar
• Products
  GlycoScope

  Qproteome GlycoArray kits
• News&Events
• R&D
• Publications
• Careers
• Contact Us

For nearly a decade, Procognia (Israel) Ltd has been active in Research & Development in the field of glycobiology, with specific world-leading expertise in glycoanalysis. The Procognia team is committed to its continued R&D programs to fortify the company's capabilities in the fields of glycobiology and biosimilar drug development.  

Partners

Procognia's Research & Development team works in close contact with companies and academic research centers in the areas of glycobiology and biosimilars. These collaborative business and scientific partnerships strengthen Procognia in the quest to develop the most advanced and efficient technologies for biosimilar drug development processes.

Glycomarkers/Biomarkers

Biomarker research is an important and rapidly growing field, enabling the prediction of disease onset, progression and drug responsiveness. Procognia's ongoing research in Glycomarkers plays a significant role in the advancement of Theranostics/Personalized Medicine.

Glycodiagnostics

Glycodiagnostics is a field that assesses changes in glycosylation in clinical samples. Changes in glycosylation have been observed during disease progression, including cancer progression and aggressiveness. Procognia is renowned for its breakthrough research and development in the field of glycodiagnostics, and holds a number of validated and proprietary applications.

Procognia is currently involved in an EU Consortium developing glycoanalysis methods for the early diagnosis and monitoring of cancer stages, based on analysis of serum samples.

Stem Cells Research

Procognia has developed a method for comparative glycoanalysis of membrane protein extracts from cultured cells. The method enables the assessment of differences in glycosylation patterns of membrane proteins from two comparable cell populations, such as before and after drug treatment, before and after differentiation, metastatic and non-metastatic cancer cells, and others. The method was recently applied in a study of adipogenic and osteogenic differentiation of mesenchymal stem cells.